The Novartis Malaria Initiative

Michael  Chu; Vincent Marie Dessain; Emilie  Billaud

Case | HBS Case Collection | March 2014 (Revised July 2014)

The Novartis Malaria Initiative

by Michael Chu, Vincent Marie Dessain and Emilie Billaud

Abstract

The Novartis Malaria Initiative was designed, as a result of a precedent–setting agreement with the World Health Organization in 2001, to provide a breakthrough treatment for malaria—"at no profit"—for public health systems. What had begun as an exemplary act of corporate responsibility had succeeded beyond any expectations. In 2012, for the second year in a row, Novartis had manufactured and distributed over 100 million units of the anti–malarial drug Coartem ®. But with the significantly increased volumes came increased costs, bringing into question the sustainability of the program. In 2013, Dr. Linus Igwemezie, executive vice president and head of the Novartis Malaria Initiative, reflected on the evolution of the program and the way forward. His goal was to expand access to Coartem in the private sector through a low-margin, high-volume social business model to eventually enable the Malaria Initiative to break even and become financially sustainable. Was this the right strategy?

Keywords: Health Care and Treatment; Product Marketing; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Switzerland; Africa; Nigeria;

Language: English

Format: Print

32 pages

Educators Purchase

Citation:

Chu, Michael, Vincent Marie Dessain, and Emilie Billaud. "The Novartis Malaria Initiative." Harvard Business School Case 314-103, March 2014. (Revised July 2014.)

In 2018, Henri Seydoux, CEO and Founder of Parrot, believed that his company was at an inflection point in its history. Parrot had been a European leader in consumer electronics since the 1990s, first developing Bluetooth kits for cars before moving on to electronic toys and, significantly, the AR Drone in 2010—a remote-controlled quadcopter that was way ahead of its time. In the years that followed, Parrot’s sales volumes and popularity quickly increased. But new players were entering the market. Giant Chinese rival DJI, in particular, aggressively lowered its prices, forcing weaker companies out of the market. If Parrot was to survive the shakeout, Seydoux would have to figure out how to compete in an industry where even well-capitalized companies were collapsing. The questions that he faced were both strategic and urgent. Where to compete and how to win?

After long dominating Mexican microfinance, Compartamos Banco faces the emergence of fintech, just as for the first time its loan portfolio and clients have declined. Enrique Majós, CEO of GENTERA, the bank´s parent company, is keenly aware of the profound changes since the Compartamos IPO in April 2007, when it was valued at $1.5 billion and became the first bank wholly dedicated to microfinance to be quoted in a major stock exchange. Since then, the market has become intensely competitive, with both large established institutions and new entrants vying for the same customers. Simultaneously, the digital era has spawned fintech, threatening to disrupt Compartamos’ highly successful model but also providing opportunities for the bank to reshape it. While challenged to manage key innovation within a leading incumbent, Majós must consider whether to commit his team to a major cost reduction in the next few years to his board of directors at their next meeting at the end of the month.

Faculty & Research

The Novartis Malaria Initiative

Abstract

Citation:

About the Author

More from the Author

Faculty & Research

The Novartis Malaria Initiative

Abstract

Citation:

Related Work

About the Author

More from the Author